Benefits of mRNA cancer vaccines could exceed $75 billion in US alone
An analysis of ongoing trials suggests that mRNA cancer vaccines have the potential to deliver health benefits worth $75 billion each year in the US alone
Health
An analysis of ongoing trials suggests that mRNA cancer vaccines have the potential to deliver health benefits worth $75 billion each year in the US alone
30 December 2025
Facebook / Meta Twitter / X icon Linkedin Reddit Email
The mRNA cancer vaccines now in development come with large economic benefits
Eugene/Getty Images
In August 2025, the US cut half a billion dollars in funding for vaccine development. This put the potential benefits of mRNA cancer vaccines at risk – benefits that could be worth around $75 billion a year in the US alone, according to an estimate by Alison Galvani at Yale University and her colleagues.
“The therapeutic progress demonstrated by each of the clinical trials in our analysis has the potential to avert nearly 50,000 deaths, with an economic value of $75 billion,” the team writes. “These estimates represent only a single annual cohort of patients treated for their respective cancer.”
Curtailing federal investment in mRNA vaccine technology risks forfeiting these benefits, the researchers warn.